Evidence map›Paper›PMID 42177380›Full record

ArticlePituitary2026

Determinants of remission and recurrence following transsphenoidal surgery for prolactinoma: a single-center experience.

William M Burns, Gurkirat Kohli, Lu Wang, George Kassis, Nicholas Contento, Prasanth Romiyo, Samia Lopa, Ismat Shafiq, G Edward Vates

Abstract read
PubMed Publisher
In one paragraph

Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

William M BurnsDepartment of Neurosurgery, University of Rochester Medical Center, Rochester, NY, USA.
Gurkirat KohliDepartment of Neurosurgery, University of Rochester Medical Center, Rochester, NY, USA.
Lu WangDepartment of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, USA.
George KassisDepartment of Neurosurgery, University of Rochester Medical Center, Rochester, NY, USA.
Nicholas ContentoDepartment of Neurosurgery, University of Rochester Medical Center, Rochester, NY, USA.
Prasanth RomiyoDepartment of Neurosurgery, University of Rochester Medical Center, Rochester, NY, USA.
Samia LopaDepartment of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, USA.
Ismat ShafiqDepartment of Neurosurgery, University of Rochester Medical Center, Rochester, NY, USA.
G Edward VatesDepartment of Neurosurgery, University of Rochester Medical Center, Rochester, NY, USA. edward_vates@urmc.rochester.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo identify clinical, radiographic, and biochemical predictors of acute surgical remission (ASR), long-term remission (LTR), and recurrence in patients undergoing endoscopic transsphenoidal surgery (ETSS) for prolactinoma.

methodsA retrospective cohort study was conducted on 52 patients who underwent ETSS for histologically confirmed prolactinoma at a single center between 2010 and 2022.

resultsRemission was more likely in patients with microadenomas (ASR 72.2% vs. 41.2% macroadenomas, p = 0.03; LTR 44.4% vs. 17.6%, p = 0.052), Knosp 0-1 tumors (ASR 66.7% vs. 18.8% Knosp 2-4, p = 0.001; LTR 38.9% vs. 0%, p = 0.004), absence of cavernous sinus invasion (ASR 62.2% vs. 26.7%, p = 0.02; LTR 37.8% vs. 0%, p = 0.005), completely resected tumors (ASR 75.0% vs. 25.0%, p < 0.001; LTR 50.0% vs. 0%, p < 0.001). Patients achieving LTR had lower postoperative prolactin (4.5 vs. 28.0 ng/mL, p = 0.01). Median follow-up duration was 5.6 years, and median time to recurrence was 2.6 years. Recurrence was associated with higher peak prolactin (HR 1.003 per ng/mL, 95% CI: 1.001-1.01, p = 0.01), Knosp 2-4 tumors (HR 5.64, 95% CI: 1.40-22.80, p = 0.02), cavernous sinus invasion (HR 3.97, 95% CI: 1.15-13.64, p = 0.03), subtotal resection (HR 0.19 for GTR, 95% CI: 0.06-0.60, p = 0.01), and higher postoperative prolactin (HR 1.13 per ng/mL, 95% CI: 1.04-1.23, p = 0.01).

conclusionTumor size, invasiveness, extent of resection, and prolactin levels are key predictors of remission and recurrence. These findings underscore risk-stratified decision-making and long-term surveillance.

Indexed as

Pituitary NeoplasmsProlactinomaAdultCavernous SinusFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalProlactinRemission InductionRetrospective StudiesProlactinEndoscopic transsphenoidal surgeryLong-term remissionPituitary adenomaProlactinoma

Identifiers

PMID42177380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.